BioNTech SE
BNTXBioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Drugs in Pipeline
45
Phase 3 Programs
23
Upcoming Catalysts
7
Next Catalyst
This month
Market Overview
Stock performance and key metrics
7 upcoming, 1 past
How BNTX's past catalysts played out
Investigational Influenza Vaccine
Influenza,Human
BNT162b2
SARS-CoV-2 Infection
BNT113
Unresectable Head and Neck Squamous Cell Carcinoma
BNT162b1
SARS-CoV-2 Infection
Biological/Vaccine: BNT162b2 10mcg
SARS-CoV-2 Infection, COVID-19
BNT162b2 OMI
SARS-CoV-2 Infection
BNT162b2 (Omi XBB.1.5)
SARS-CoV-2 Infection
BNT162b5 Bivalent (WT/OMI BA.2)
SARS-CoV-2 Infection
Seasonal Inactivated Influenza Vaccine
SARS-CoV-2 Infection
Influenza and COVID-19 Combination A
Influenza
BNT162b2 (2025/2026 formulation)
COVID-19
Pembrolizumab
Non-small Cell Lung Cancer
BNT162b2.B.1.351
SARS-CoV-2 Infection
BNT162b2 (Omi LP.8.1)
COVID-19
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
SARS-CoV-2 Virus
Pumitamig
Extensive-stage Small-cell Lung Cancer
BNT162b2 Vaccine
COVID-19
Carboplatin
Extensive-stage Small-cell Lung Cancer
Paclitaxel
Endometrial Cancer
Gemcitabine
Breast Neoplasms
BNT324
Advanced Lung Cancer
Docetaxel
Non-small Cell Lung Cancer
Prednisone/prednisolone
Metastatic Castration-resistant Prostate Cancer
BNT329
Advanced Solid Cancers
BNT326
Advanced Solid Tumor
BNT162b3
Covid-19
BNT111
Melanoma Stage III
BNT166a
Monkeypox
BNT323
Locally Advanced Breast Cancer
BNT314
Metastatic Colorectal Cancer
bivalent BNT162b2 (original/Omi BA.4/BA.5)
Influenza, Human
BNT162b2s01
COVID-19
Investigational COVID-19 Vaccine
Influenza
BNT327
Non-small Cell Lung Cancer
BNT142
Solid Tumor
Temozolomide
Recurrent Glioblastoma
BNT165e
Malaria
BNT3212
Advanced Solid Tumor
BNT3214
Advanced Solid Tumor Cancer
Nab-paclitaxel
Pancreatic Ductal Adenocarcinoma (PDAC)
BNT162a1
Infections, Respiratory
RO7198457 intravenous (IV)
Colorectal Cancer Stage II
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
SARS-CoV-2 Infection
BNT164a1
Tuberculosis
BNT327 Dose Level 1 (DL2)
Locally Advanced Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Investigational Influenza Vaccine | Phase 3 | Influenza,Human | - | - |
BNT162b2 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma | - | - |
BNT162b1 | Phase 3 | SARS-CoV-2 Infection | - | - |
Biological/Vaccine: BNT162b2 10mcg | Phase 3 | SARS-CoV-2 Infection, COVID-19 | - | - |
BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi XBB.1.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | SARS-CoV-2 Infection | - | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | SARS-CoV-2 Infection | - | - |
Influenza and COVID-19 Combination A | Phase 3 | Influenza | - | - |
BNT162b2 (2025/2026 formulation) | Phase 3 | COVID-19 | - | - |
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - | - |
BNT162b2.B.1.351 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi LP.8.1) | Phase 3 | COVID-19 | - | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
BNT162b2 Vaccine | Phase 3 | COVID-19 | - | - |
Carboplatin | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
Paclitaxel | Phase 3 | Endometrial Cancer | - | - |
Gemcitabine | Phase 3 | Breast Neoplasms | - | - |
BNT324 | Phase 3 | Advanced Lung Cancer | - | - |
Docetaxel | Phase 3 | Non-small Cell Lung Cancer | - | Patent 2036 |
Prednisone/prednisolone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
BNT329 | Phase 2 | Advanced Solid Cancers | - | - |
BNT326 | Phase 2 | Advanced Solid Tumor | - | - |
BNT162b3 | Phase 2 | Covid-19 | - | - |
BNT111 | Phase 2 | Melanoma Stage III | - | - |
BNT166a | Phase 2 | Monkeypox | - | - |
BNT323 | Phase 2 | Locally Advanced Breast Cancer | - | - |
BNT314 | Phase 2 | Metastatic Colorectal Cancer | - | - |
bivalent BNT162b2 (original/Omi BA.4/BA.5) | Phase 2 | Influenza, Human | - | - |
BNT162b2s01 | Phase 2 | COVID-19 | - | - |
Investigational COVID-19 Vaccine | Phase 2 | Influenza | - | - |
BNT327 | Phase 2 | Non-small Cell Lung Cancer | - | - |
BNT142 | Phase 2 | Solid Tumor | - | - |
Temozolomide | Phase 2 | Recurrent Glioblastoma | - | - |
BNT165e | Phase 2 | Malaria | - | - |
BNT3212 | Phase 2 | Advanced Solid Tumor | - | - |
BNT3214 | Phase 2 | Advanced Solid Tumor Cancer | - | - |
Nab-paclitaxel | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
BNT162a1 | Phase 2 | Infections, Respiratory | - | - |
RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II | - | - |
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | SARS-CoV-2 Infection | - | - |
BNT164a1 | Phase 2 | Tuberculosis | - | - |
BNT327 Dose Level 1 (DL2) | Phase 2 | Locally Advanced Breast Cancer | - | - |
SARS-CoV-2 Infection
8 drugs in this indication
COVID-19
4 drugs in this indication
Non-small Cell Lung Cancer
3 drugs in this indication
Advanced Solid Tumor
2 drugs in this indication
Influenza
2 drugs in this indication
Influenza, Human
2 drugs in this indication
Locally Advanced Breast Cancer
2 drugs in this indication
Extensive-stage Small-cell Lung Cancer
1 drug in this indication
Unresectable Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Advanced Solid Cancers
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
Advanced Lung Cancer
1 drug in this indication
Colorectal Cancer Stage II
1 drug in this indication
Monkeypox
1 drug in this indication
SARS-CoV-2 Virus
1 drug in this indication
Tuberculosis
1 drug in this indication
Solid Tumor
1 drug in this indication
Malaria
1 drug in this indication
SARS-CoV-2 Infection, COVID-19
1 drug in this indication
Infections, Respiratory
1 drug in this indication
Melanoma Stage III
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioNTech SE's drug pipeline?→
CatalystAlert tracks 45 drug candidates in BioNTech SE's (BNTX) pipeline across Phase 3, Phase 2. Its lead program is Investigational Influenza Vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioNTech SE's next FDA catalyst?→
BioNTech SE's (BNTX) next tracked catalyst is a Phase 3 expected July 23, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BNTX biotech catalysts?→
Add BNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioNTech SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.